ストックスクリーナーアプリを入手
11.19
0.45%
0.05
アフターアワーズ：
11.19
前日終値:
$11.14
開ける：
$11.05
24時間の取引高:
101.12K
Relative Volume:
0.49
時価総額：
$462.06M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-11.61%
1か月 パフォーマンス:
+12.01%
6か月 パフォーマンス:
-40.38%
1年 パフォーマンス:
-51.45%
1日の値動き範囲:
$10.76
$11.72
1週間の範囲:
$10.76
$14.43
52週間の値動き範囲:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
RAPP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
11.19 | 462.06M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-08 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
Rapport Therapeutics Inc (RAPP) 最新ニュース
California State Teachers Retirement System Purchases 7,886 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Rapport Therapeutics management to meet with Citizens JMP - TipRanks
Deutsche Bank AG Invests $41,000 in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Stifel reiterates buy rating for Rapport Therapeutics stock By Investing.com - Investing.com Nigeria
Citizens JMP maintains positive outlook on Rapport Therapeutics stock By Investing.com - Investing.com UK
Rapport Therapeutics Completes Enrollment for Phase 2a Trial - TipRanks
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - GlobeNewswire
Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline - Nasdaq
How the (RAPP) price action is used to our Advantage - news.stocktradersdaily.com
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Monday - Defense World
Rapport Therapeutics to Host 2025 Investor and Analyst Day - GlobeNewswire
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth - Yahoo Finance
Rapport Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Grows Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Buys 5,634 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics, Inc. SEC 10-Q Report - TradingView
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update - The Manila Times
(RAPP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by JPMorgan Chase & Co. - Defense World
Legal & General Group Plc Buys 8,614 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by Geode Capital Management LLC - Defense World
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
When the Price of (RAPP) Talks, People Listen - news.stocktradersdaily.com
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia
Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World
Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World
JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq
Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada
(RAPP) Investment Analysis - news.stocktradersdaily.com
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Validea Kenneth Fisher Strategy Daily Upgrade Report3/25/2025 - Nasdaq
Vanda Pharmaceuticals (NASDAQ:VNDA) and Rapport Therapeutics (NASDAQ:RAPP) Financial Contrast - Defense World
Rapport Therapeutics Inc (RAPP) 財務データ
Rapport Therapeutics Inc (RAPP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Rapport Therapeutics Inc (RAPP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bredt David | Chief Scientific Officer |
Apr 15 '25 |
Sale |
9.57 |
8,500 |
81,310 |
460,642 |
| Bredt David | Chief Scientific Officer |
Mar 14 '25 |
Sale |
10.85 |
8,500 |
92,205 |
469,142 |
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):